FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1625-1626 November 14, 2002 Number 20 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Antin, J. H. Related Article by Antin, J. H. PubMed Citation

To the Editor: In his Clinical Practice article (July 4 issue),¹ Antin does not discuss an important cause of late death after hematopoietic stem-cell transplantation: invasive fungal infection. Several centers have reported that such infections (such as invasive aspergillosis) occur in up to 15 percent of recipients of allogeneic hematopoietic stem-cell transplants and are most commonly encountered in the late phase.² Chronic graft-versus-host disease and therapy with corticosteroids are important risk factors for these infections.² With increasing treatment options that include azole antifungal agents, aggressive diagnostic workup and treatment should be pursued; prophylaxis with azoles in patients at highest risk . . . [Full Text of this Article]

This article has been cited by other articles:

• Einsele, H., Reusser, P., Bornhauser, M., Kalhs, P., Ehninger, G., Hebart, H., Chalandon, Y., Kroger, N., Hertenstein, B., Rohde, F., for the EBMT Working Group on Infectious Disease, (2006). Oral valganciclovir leads to higher exposure to ganciclovir than intravenous ganciclovir in patients following allogeneic stem cell transplantation. Blood 107: 3002-3008 [Abstract] [Full Text]